Revolutionizing Cancer Treatment with Cutting-Edge Oncolytic Hairpin DNA Technology
TKG Therapeutics, Inc. is a Japan-based biotechnology company, established on April 1, 2022, with a mission to transform cancer treatment through the development of innovative, targeted therapies using our breakthrough Oncolytic Hairpin DNA technology. Our strong collaborative network of experts and research partners is the driving force behind our groundbreaking research.
Located at the South Research Building of The University of Tokyo, we are proud to work in close collaboration with our distinguished research partners, including The University of Tokyo to accelerate the development and commercialization of our innovative technology.
At TKG Therapeutics, Inc., we are dedicated to transforming the landscape of cancer therapy by developing innovative, targeted treatments with the potential to save millions of lives. Our groundbreaking Oncolytic Hairpin DNA Pair technology is poised to revolutionize cancer treatment by offering a highly selective and immune-activating therapy that targets cancer cells with high miRNA expression.
Our Oncolytic Hairpin DNA Pair technology has demonstrated promising results in both in vitro and in vivo experiments, selectively killing cancer cells while leaving healthy cells unharmed. By harnessing the power of microRNA-triggered DNA self-assembly, our technology induces innate immune activation, specifically targeting the cGAS-STING pathway - a universal innate immune mechanism present in most patients and cancer cells.
High Selectivity: Targets cancer cells with high miRNA expression, a common feature in various types of cancers, while sparing healthy cells to minimize side effects.
Immune Activation: Stimulates the body's natural immune response against cancer cells by selectively activating the cGAS-STING pathway.
Versatile Treatment: With over 1,000 different miRNAs related to various cancers, our technology holds the potential to treat a wide range of tumor types.
Combination Therapy Potential: Our hairpin DNA system can be combined with existing immune checkpoint inhibitors for a more effective and comprehensive cancer immunotherapy approach.
Join us at TKG Therapeutics, Inc. as we embark on a journey to revolutionize cancer treatment and improve the lives of patients worldwide.
所在地: 〒113-8485 東京都文京区本郷７丁目３ー１ 東京大学南研究棟アントレプレナーラボ